Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SaTX-2
- Development stage
- Preclinical
- Lead developer
- StarkAge Therapeutics
01
Overview
SaTX-2 is an early-stage senolytic drug candidate under development by StarkAge Therapeutics. The program is designed to selectively target and eliminate senescent cells, which are non-dividing cells that accumulate with age and contribute to chronic inflammation, cancer metastasis, and resistance to chemotherapy. As of 2024, the specific molecular target and therapeutic modality for SaTX-2 have not been publicly disclosed, and the program remains in the discovery phase following a fundraising round in May 2024. The company's broader platform focuses on identifying biomarkers of senescence to develop targeted therapies, such as antibody-drug conjugates, that can clear detrimental senescent cells while sparing beneficial ones.
Beyond the preview
Go deeper on SaTX-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SaTX-2.